(Q41438321)

English

Inhibitory effects of analogs of luteinizing hormone-releasing hormone on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer

scientific article published on October 1994

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Inhibitory effects of analogs of luteinizing hormone-releasing hormone on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

author name string

J Pinski

1

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

H Reile

2

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

G Halmos

3

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

K Groot

4

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

language of work or name

0 references

publication date

1 October 1994

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

International Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

59

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

51-55

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

The effects of gonadotrophin releasing hormone analogues in prostate cancer are mediated through specific tumour receptors

1 reference

https://api.crossref.org/works/10.1002%2FIJC.2910590112

21 January 2018

Insulin-like growth factor I: action and receptor characterization in human prostate cancer cell lines

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/IJC.2910590112

Growth inhibition of estrogen-dependent and estrogen-independent MXT mammary cancers in mice by the bombesin and gastrin-releasing peptide antagonist RC-3095

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/IJC.2910590112

Standardized kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activity

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/IJC.2910590112

Metastatic model for human prostate cancer using orthotopic implantation in nude mice

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/IJC.2910590112

LIGAND: A versatile computerized approach for characterization of ligand-binding systems

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/IJC.2910590112

Production of epidermal growth factor and transforming growth factor-alpha by the androgen-responsive LNCaP human prostate cancer cell line

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/IJC.2910590112

Mitogenic effects of insulin and insulin-like growth factors on PA-III rat prostate adenocarcinoma cells: characterization of the receptors involved

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/IJC.2910590112

Growth factor involvement and oncogene expression in prostatic tumours

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/IJC.2910590112

Effects of epidermal growth factor and analogues of luteinizing hormone-releasing hormone and somatostatin on phosphorylation and dephosphorylation of tyrosine residues of specific protein substrates in various tumors

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/IJC.2910590112

Androgens stimulate both growth rate and epidermal growth factor receptor activity of the human prostate tumor cell LNCaP.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/IJC.2910590112

New antagonists of LHRH. II. Inhibition and potentiation of LHRH by closely related analogues.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/IJC.2910590112

Receptors for luteinizing hormone-releasing hormone, somatostatin, prolactin, and epidermal growth factor in rat and human prostate cancers and in benign prostate hyperplasia

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/IJC.2910590112

Measurement of insulin-like growth factor-II in physiological fluids and tissues. I. An improved extraction procedure and radioimmunoassay for human and rat fluids

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/IJC.2910590112

Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/IJC.2910590112

Present status of agonistic and antagonistic analogs of LH-RH in the treatment of advanced prostate cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/IJC.2910590112

Identifiers

10.1002/IJC.2910590112

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41438321&oldid=2097714728"